Believe it or not, it's reasonable to think that B of A's stock could soon trade for $20 a share or more.
How much do you really know about Social Security?
All biotechs face uncertain futures, but these three are so risky, we wouldn't touch them with a rented barge pole.
Chipotle's temporary rewards program ends this month, so it needs to think about what October will bring.
Online sales haven't hurt Foot Locker, Inc. as much as investors may have feared.
I don't think anyone was predicting that NVIDIA, Trex Company, and frack sand stocks would have a great 2016.
As Hillary Clinton's numbers take a hit in the polls, the Democratic ticket is deploying a potentially potent surrogate to the campaign trail: Anne Holton.
Motley Fool co-founder David Gardner is a longtime fan of the premium coffeehouse chain and its CEO. Here are a few reasons why.
Some analysts are forecasting near-term doom and gloom for the firearms industry, but that prediction is just as unjustified this quarter as it was the last time around.
Pfizer is about to launch a biosimilar to Johnson & Johnson's top-selling Remicade.
Shares rose in response to the company posting a surprise quarterly profit.
The expiration of provisions that have been smoothing out Obamacare losses may be behind decisions by insurers to step back from the exchanges next year.
We're told to save three to six months' worth of living expenses in case an emergency strikes, but this rule doesn't apply to everyone.
Yes, it can. But does that make the stock a buy?